Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation
Open Access
- 21 April 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0154229
Abstract
The glucagon-like peptide receptor (GLP-1R), which is a G-protein coupled receptor (GPCR), signals through both Gαs and Gαq coupled pathways and ERK phosphorylation to stimulate insulin secretion. The aim of this study was to determine molecular details of the effect of small molecule agonists, compounds 2 and B, on GLP-1R mediated cAMP production, intracellular Ca2+ accumulation, ERK phosphorylation and its internalisation. In human GLP-1R (hGLP-1R) expressing cells, compounds 2 and B induced cAMP production but caused no intracellular Ca2+ accumulation, ERK phosphorylation or hGLP-1R internalisation. GLP-1 antagonists Ex(9–39) and JANT-4 and the orthosteric binding site mutation (V36A) in hGLP-1R failed to inhibit compounds 2 and B induced cAMP production, confirming that their binding site distinct from the GLP-1 binding site on GLP-1R. However, K334A mutation of hGLP-1R, which affects Gαs coupling, inhibited GLP-1 as well as compounds 2 and B induced cAMP production, indicating that GLP-1, compounds 2 and B binding induce similar conformational changes in the GLP-1R for Gαs coupling. Additionally, compound 2 or B binding to the hGLP-1R had significantly reduced GLP-1 induced intracellular Ca2+ accumulation, ERK phosphorylation and hGLP-1R internalisation. This study illustrates pharmacology of differential activation of GLP-1R by GLP-1 and compounds 2 and B.Keywords
Funding Information
- Biotechnology and Biological Sciences Research Council (BB/F017596/1)
- Biotechnology and Biological Sciences Research Council (BB/C515455/2)
- Medical Research Council (G0401232)
This publication has 50 references indexed in Scilit:
- Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 ReceptorPLOS ONE, 2012
- Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 ReceptorExperimental Diabetes Research, 2012
- Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 ReceptorExperimental Diabetes Research, 2012
- Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug ScreeningMolecular Pharmacology, 2010
- Comparative Effects of the Endogenous Agonist Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide and the Small-Molecule Ago-Allosteric Agent “Compound 2” at the GLP-1 ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 ReceptorJournal of Biological Chemistry, 2010
- Contrasting Effects of Allosteric and Orthosteric Agonists on M1 Muscarinic Acetylcholine Receptor Internalization and Down-regulationThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Selective activation of the M 1 muscarinic acetylcholine receptor achieved by allosteric potentiationProceedings of the National Academy of Sciences, 2009
- Mechanisms of action of glucagon-like peptide 1 in the pancreasPharmacology & Therapeutics, 2007
- Small-molecule agonists for the glucagon-like peptide 1 receptorProceedings of the National Academy of Sciences, 2007